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The two-faced nature of small heat shock proteins: amyloid assembly and the
inhibition of fibril formation. Relevance to disease states
Abstract
The ability of small heat-shock proteins (sHsps) such as alphaB-crystallin to inhibit the amorphous
(disordered) aggregation of varied target proteins in a chaperone-like manner has been well described.
The mechanistic details of this action are not understood. Amyloid fibril formation is an alternative offfolding pathway that leads to highly ordered beta-sheet-containing aggregates. Amyloid fibril formation is
associated with a broad range of protein conformational diseases such as Alzhiemer's, Parkinson's and
Huntington's and sHsp expression is elevated in the protein deposits that are characteristic of these
disease states. The ability of sHsps to prevent fibril formation has been less well characterised. It has
been shown, however, that sHsps are potent inhibitors of fibril formation of a range of target proteins. In
this chapter, the disease-related significance of this observation is discussed. Interestingly, in addition to
being effective molecular chaperones, alphaA- and alpaB-crystallin themselves, along with some of their
peptide fragments, readily form amyloid fibrils under slightly destabilising solution conditions. The
implications of this observation in terms of protein conformational diseases, e.g. cataract, along with the
potential nanotechnological applications of these fibrils, are discussed.
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1. Protein folding, misfolding and aggregation: the role of molecular chaperones
Globular proteins do not exist as structured, folded entities for their entire life. For example, after
synthesis, the polypeptide chain is unstructured and must fold to its correct three-dimensional,
functional conformation. To cross a biological membrane or move from one cellular compartment to
another, a protein must unfold from its native state. Furthermore, if a protein is subject to stress, e.g.
elevated temperature, low pH, oxidative conditions etc., it may partially unfold to adopt intermediately
folded states. Many of these intermediately folded states have characteristics of molten globule states,
i.e. they have elements of secondary structure but little or no tertiary structure, and are dynamic
species with an expanded structure relative to the native state and have their hydrophobic core exposed
to solution. The greater exposure of hydrophobicity to solution encourages protein misfolding, mutual
association (aggregation) and potentially, precipitation. The cell has various mechanisms available to
counteract these processes of which arguably the most important is the utilisation of molecular
chaperones, a large group of structurally unrelated proteins which interact with destabilised proteins to
prevent their aggregation and facilitate their correct fold [1]. Expression of molecular chaperones is
increased under stress conditions, e.g. elevated temperature. Hence, they are often known as heatshock proteins (Hsps). Thus, for a newly synthesised protein in the crowded environment of the cell,
ATP-dependent molecular chaperones such as Hsp70 and Hsp60 ensure high fidelity of protein folding
and assembly [1]. In this process, Hsp70 interacts initially with the unfolded, nascent polypeptide
chain, specifically with extended regions of the chain. If the protein requires further encouragement to
fold correctly, it is sequestered into the large cavity of the Hsp60 aggregate, where it can be isolated
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from the surrounding cellular milieu, and fold via repeated interactions with the wall of the Hsp60
cavity [1]. If a protein is irretrievably misfolded and therefore incapable of folding properly, e.g. as a
result of mutation, it may be labelled with ubiquitin and thereby targeted for degradation into its
constituent amino acids via the proteasome, a large multi-subunit ordered complex with a large central
cavity into with the targeted protein is inserted and digested.
The folding pathway for a protein proceeds via a series of intermediately folded states and is relatively
rapid (Figure 1). Most newly synthesised proteins fold in a few milliseconds from their unstructured
state so that the intermediates are only transiently present. However, if they linger for too long, e.g.
because of difficulty in folding, mutation or due to cellular stress, these states may associate and enter
the slow off-folding pathways which, if not recognised by the ubiquitin/proteasome system, eventually
lead to precipitated amorphous or amyloid fibril aggregates (Figure 1). In many cases, aggregation and
precipitation of proteins are highly deleterious to cell viability and are hallmarks of protein misfolding
diseases (more below). In all these diseases, with the possible exception of cataract [2], the
precipitated state of the proteins is highly ordered, existing in a cross β-sheet array arranged into long
amyloid fibrils (more below) [3-5]. By contrast, as the name implies, the amorphous aggregation
pathway is composed of cellular aggregates that are relatively disordered in arrangement. Both
pathways arise from association of intermediately folded states of proteins via a nucleation-dependent
mechanism (Figure 1). In the case of the amorphous aggregation pathway, this leads to the formation
of aggregates that when a critical size (a nucleus) is reached, readily sequester other intermediates and
form large aggregates that are intrinsically unstable and precipitate [6, 7].
Intracellularly, a unique class of ubiquitous and abundant ATP-independent molecular chaperones, the
small heat-shock proteins (sHsps), interacts specifically with partially folded proteins that enter the
off-folding protein aggregation pathways (Figure 2). The ability of sHsps to prevent amorphous
protein aggregation was described over 15 years ago [8] and led to major research activity in relation
to the principal lens protein α-crystallin, a sHsp, and its involvement in the prevention of protein
aggregation in the lens and hence cataract formation [6]. A mechanism for this action has been
proposed (see Figure 2 for a description) [6, 9], although specific details, at the atomic level, about the
mechanism of sHsp chaperone action are not known.

2. Amyloid fibrils: mechanism of formation, structure and their association with disease.
The reasons for a protein entering either the amorphous or amyloid fibril-forming, off-folding
pathways are not entirely understood but may involve one or more of the following factors:
1. The amino acid sequence of the protein: some sequences are more prone to fibril formation since
the physiochemical properties of the amino acids are highly influential on fibril-forming propensity of
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a polypeptide sequence [10-12]. For example, factors such as charge, hydrophobicity and propensity to
adopt a β-sheet configuration are likely to play important roles. There are a variety of algorithms
available to predict the fibril-forming propensity of amino acid sequences [12-15].
2. The kinetics of aggregation, with a slow aggregation rate favouring ordered, amyloid fibril
formation.
3. The ‘nature’ of the intermediate state from which aggregation occurs, i.e. what elements of
secondary structure (e.g. β-sheet in the case of amyloid fibril formation) are in place within the
intermediate to facilitate protein association and aggregation along either pathway.

The misfolding, and subsequent formation of amyloid fibrils, of a normally soluble protein or peptide
precursor, is associated with a variety of debilitating diseases, including Alzheimer’s disease (AD),
Parkinson’s disease, Creutzfeldt-Jakob and Mad-Cow disease, Huntington’s disease and type IIdiabetes [5, 7, 16-18]. The incidence of many of these diseases will grow over the next 20-30 years as
the population ages. In each case, the proteinaceous deposits or plaques that are hallmarks of the
disease predominately consist of one protein or peptide, for example amyloid-β peptides (Aβ) in AD,
α-synuclein in Parkinson’s, prion protein in Creutzfeldt-Jakob, huntingtin in Huntington’s and amylin
in type II-diabetes. The severity of the disease, however, does not necessarily correlate with the extent
of amyloid deposition [16], and precursors to amyloid fibrils, or small oligomeric species in particular,
are believed to be especially toxic to cells [19, 20], although, the mature fibril can also be toxic [21,
22], and the most cytotoxic species may vary depending on the fibril-forming protein.
Amyloid fibrils are long thread-like protein aggregates typically 2-10 nm in diameter and ranging from
one to many microns in length, as visualized by transmission electron microscopy (TEM) [23] and
atomic force microscopy (AFM) [24, 25] (Figure 3). Amyloid fibrils are characterized by a ‘cross-β’
X-ray fibre diffraction pattern arising from a predominantly β-sheet structure, comprising two major
anisotropic reflections: a meridional reflection at 4.7 Å, corresponding to the distance between βstrands, and an equatorial reflection, ca. 9-11 Å, corresponding to the distance between β-sheets [26,
27] (Figure 3). The anisotropy arises since the two aforementioned distances are perpendicular to each
other; the β-strands align to form β-sheets, stabilized by extensive hydrogen bonding that run
throughout the length of the fibrils, and these β-sheets stack to form protofilaments, which in turn
assemble in a helical fashion to comprise a ‘mature’ amyloid fibril [28-30]. Fibrils exhibit a positive
interaction with the dyes Congo red and thioflavin T (ThT) and hence these dyes are frequently used to
monitor amyloid fibril assembly [31, 32]. It has been proposed that intercalation of the dye molecules
into the extended β-sheet structure of the fibrils gives rise to either a characteristic spectral spectral
shift for Congo red or a change in the fluorescence properties/emission intensities of ThT [33]. A
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range of biophysical techniques (i.e. TEM, AFM, X-ray fibre diffraction, and dye binding) are useful
in characterizing amyloid fibril assembly.
The ability to assemble into amyloid fibrils has been proposed to be a generic property of polypeptide
chains [4], although the propensity of proteins to aggregate to form fibrils can vary widely depending
on the factors listed above and solution conditions [34]. The amyloid pathway proceeds via a soluble
protofibril precursor (nucleus) that acts as a template to sequester other intermediates, via a nucleationdependent mechanism, which eventually leads to the insoluble amyloid fibril [5, 34]. This mechanism
is consistent with the observed kinetics of fibril formation, as monitored using ThT or Congo red.
Thus, both the length of the lag phase (i.e. the time taken to form a stable nucleus) and the rate of
elongation are highly dependent on the protein concentration through their reliance on the
concentration of partially folded intermediates present at any given time [35]. Whilst this nucleationdependent mechanism holds for most in vitro amyloid fibril forming species studied to date,
alternative mechanisms do exist [36].
3. Amyloid fibril formation by α-crystallin: in vitro studies.
Although renowned for their impressive chaperone ability, i.e. the capability to prevent target proteins
from aggregating amorphously or to form amyloid fibrils [37], sHsps themselves can self-assemble
into amyloid fibrils [38-41]. α-Crystallin is the principal lens protein and is comprised of two closely
related subunits, αA- and αB-crystallin. Amyloid fibril formation is observed for a variety of αcrystallin isoforms in vitro (Figure 4), as summarized by Table 1, which lists the protein source and
the relevant references describing their fibril formation. For example, both wild-type and mutant
human recombinant αA- and αB-crystallins form aggregates displaying the characteristic properties of
amyloid fibrils, including long filamentous structures as observed by TEM (Figure 4B and C), a
positive interaction with Congo red, and cross-β X-ray fibre patterns [39].
Amyloid fibrils can be produced from α-crystallins obtained from a variety of sources, including
bovine (Figure 4A) [38], deer, and sheep eye lenses [41]. Both purified α-crystallin fractions and
crude protein extracts, containing a mixture of crystallin proteins together with other unrelated minor
crystallins (β and γ) as minor components, form fibrils [41]. Although the major component from
bovine lens crude protein extracts is α-crystallin, the exact protein composition of fibrils formed from
this mixture remains to be explored, and could include incorporation of some β− and γ-crystallin
subunits within the fibrils [41], both of which form fibrils on their own in vitro [38, 42, 43]. Recently,
the highly-ordered nature of amyloid fibrils has generated significant research interest within the
nanotechnology industry as self-assembling nanofibres, with potentially wide ranging applications as
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gelation agents, viscosifiers, nanowires and scaffolds for cellular support and for enzyme
immobilisation [44-46]. Crude bovine crystallin protein extracts represent an industrial waste product
from the meat industry. It has been suggested that the ability to form fibrils from this crude mixture,
without the need for time-consuming and expensive purification procedures, could be advantageous in
the large-scale production of fibrils as bionanomaterials [41].
3.1 Solution conditions that induce α-crystallin amyloid fibril assembly in vitro.
Fibril formation by α-crystallin is favoured when it is subjected to partially denaturing conditions and
incubation at elevated temperature, i.e. sufficient destabilization of the native state is required to give
the protein the opportunity to rearrange and self-assemble into amyloid fibrils [38], as has been
observed in other amyloid-forming systems [47, 48]. For example, bovine α-crystallin (as isolated
from the lens and containing αA- and αB-crystallin subunits) forms amyloid fibrils when incubated at
elevated temperature (60 °C) with 10 % (v/v) trifluoroethanol at acidic pH or with 1 M guanidine
hydrochloride at neutral pH (Figure 4A; lower concentrations of guanidine hydrochloride were found
insufficient to induce amyloid formation within 24 hours) [38]. Real-time 1D 1H NMR spectroscopy
was employed to monitor the time course for fibril formation by αB-crystallin and confirmed that
major unfolding of the native protein precedes self-assembly into fibrils [39]. The 1H NMR spectrum
of the native αB-crystallin oligomer is well-resolved and arises solely from a solvent-exposed, flexible
and unstructured 12-residue C-terminal extension. Resonances from the remaining part of the protein
are not observed by 1H NMR spectroscopy because the large native aggregate (mass of ~600 kDa)
tumbles slowly [49, 50]. During amyloid fibril assembly by αB-crystallin, however, 1H NMR
resonances in the aromatic region of the spectrum became visible for a brief period during the early
stages of aggregation [39]. Given that all the aromatic residues for αB-crystallin are located in the Nterminal and central (α-crystallin) domains, the implication is that these regions partially unfold prior
to fibril formation [39].
3.2 Fibril formation by peptides derived from αA-crystallins.
Cross-linking studies have identified regions of αA-crystallin responsible for binding to proteins
undergoing amorphous aggregation [51]. Synthesized peptides corresponding to these regions inhibit
both amorphous target protein aggregation [51] and amyloid fibril formation [40]. For example,
residues 71-88, (αAC(71-88)), corresponding to a putative chaperone target protein binding site,
inhibit amyloid fibril formation by Aβ(1-40) [40]. Interestingly, αAC(71-88) itself assembles into
amyloid fibrils in vitro at pH 7.5 and 37°C [40]. The ability of this αA-crystallin peptide to form
amyloid fibrils is, however, suppressed when it is mixed with Aβ(1-40), suggesting that the chaperone
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activity and the propensity to form amyloid fibrils may be closely linked. The link between chaperone
action and amyloid fibril formation is further supported by the observation that residue F71 in αAcrystallin is important for both properties; removal of F71 from αAC(71-88) stifled both of these
activities [40].

The close links between these apparently opposing behaviours, i.e. the ability to inhibit aggregation
and also to self-aggregate, may be rationalized when the mechanism of sHsp chaperone activity is
taken into account. The aptitude of sHsps to be effective chaperones arises, at least in part, from their
sequences containing hydrophobic regions, such as amino acids 71-88 in αA-crystallin, that facilitate
their interaction with exposed hydrophobic patches on partially unfolded target proteins to prevent
their aggregation [52]. Whereas on one hand this property is useful for chaperone activity, on the other
hand it may have detrimental consequences, since hydrophobic sequences also have a high propensity
to aggregate and are prone to forming amyloid fibrils [10], as was observed for αAC(71-88) [40]. Fulllength sHsp sequences may have evolved to counteract this issue, for example by flanking
hydrophobic sequences with residues likely to suppress aggregation. This could include charged
residues or flexible hydrophilic regions, that are likely to hinder aggregation [11, 12, 53]. Indeed,
αAC(70-88), which has an extra lysine residue at the N-terminus, did not form fibrils [40], indicating
that the charged K70 residue may play an important role in suppressing amyloid fibril formation in
full-length αA-crystallin. The hydrophilic and highly flexible 10-12 amino acid C-terminal extensions
of αA- and αB-crystallin [49, 50] may also play a role in hindering amyloid fibril formation by these
proteins since they are likely to discourage formation of inter-molecular contacts that could lead to
fibril formation [53].
3.3 Structural properties of fibrils formed from α-crystallins.
α-Crystallin forms fibrils with a variety of morphologies, depending on the experimental conditions
employed. For example, the level of purity of α-crystallin, prepared from bovine eye lenses, was
highly influential on the resultant fibril morphology as observed by TEM; short and curly fibrils were
formed from crude crystallin protein extracts, and long, straight fibrils arose from purified bovine αcrystallin [41]. Imaging studies of human recombinant αB-crystallin fibrils reveal unusual and
apparently branched morphologies at physiological pH in the presence of guanidine hydrochloride
(Figure 4E) [39]. These ‘mature’ fibrils, comprising multiple protofilament assemblies, were found to
unravel when the pH of solution containing the fibrils was altered (Figure 4E-G) [39]. For example,
changing the pH from 7 to 2 makes the overall charge of αB-crystallin more positive and leads to
significant repulsion between molecules, shifting the equilibrium between the protofilament
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assemblies and resulting in dissociation and large morphological changes (as assessed by AFM, Figure
4E-G) [39]. The dissociated fibrils at acidic pH displayed ‘protofibrillar’ morphologies and possessed
a relatively low elastic modulus, weak intermolecular interactions, and less regular structures in
comparison to a range of ‘mature’ amyloid fibrils formed from a variety of proteins (Figure 4F) [24].
These flexible protofibrillar morphologies readily assembled into amyloid pores (Figure 4G), similar
to those reported for other amyloid systems, e.g. apolipoprotein C-II [54, 55] and α-synuclein [56].
Interestingly, this morphology has been proposed to represent a toxic species [56, 57].

Overall, a combination of biophysical studies, including NMR spectroscopy and AFM imaging, has
revealed important insights into the structural properties of α-crystallin amyloid fibrils formed in vitro.
For example, 1H NMR studies of αB-crystallin amyloid fibrils show that the flexible C-terminal is not
incorporated into the structured cross-β sheet fibrillar core, but instead protrudes into solution [39], i.e.
the extension is flexible in both the fibrillar [39] and native αB-crystallin aggregate [49]. The Cterminal extension plays an important role in maintaining solubility of the native protein and the
oligomeric complexes it forms with target proteins in preventing their aggregation [49, 50, 58], and
therefore may also influence the solubility of the αB-crystallin fibrils.

4. Amyloid fibril formation by the small heat-shock proteins: a disease role in vivo?
Amyloid fibril formation by sHsps may be linked to disease formation, in particular lens cataract and
desmin-related cardiomyopathy (DRM). The following sections discuss these associations in detail.
4.1 Amyloid fibril formation in the eye lens: cataract and α-crystallin
Cataract is defined as opacity of the eye lens. In the healthy eye lens, transparency is thought to be
maintained by a liquid-like, short-range order that is present in highly concentrated solutions of the
crystallins [59]. The crystallins are organised in a stable supramolecular β-sheet structure within the
healthy eye lens and α-crystallin plays an important role in chaperoning the other lens crystallins (β
and γ), by suppressing aberrant aggregation that would otherwise cause light scattering and impair
vision [2]. It has been generally considered that the opacity present in cataractous lenses arises from
amorphous aggregation of the crystallin proteins. There is increasing evidence to suggest, however,
that amyloid fibril formation by crystallin proteins within the lens could be the cause of certain forms
of cataract. For example, in a murine model for cataract, a direct causal relationship was reported
between the disease state and amyloid fibril formation by a natural deletion mutant from γ-crystallin
[43]. Additionally, a connection has been reported between AD and supranuclear cataract [60]. Ex
vivo investigation of lenses from individuals with AD revealed the accumulation of Aβ peptides
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colocalised with αB-crystallin in electron dense deposits that exhibited birefringence with Congo Red
staining and a positive interaction with thioflavin S, both of which bind strongly to amyloid fibrils
[60]. These electron dense deposits correlated with the same areas of the lens where cataract was
identified by slit lamp examination. In vitro, Goldstein et al. [60] demonstrated that Aβ bound αBcrystallin with high affinity, promoting the formation of aggregates and amyloid protofibrils. Overall,
it was suggested that the presence in the lens of Aβ may promote protein aggregation, amyloid fibril
formation and supranuclear cataract [60].
There is no direct in vivo evidence, however, to show that fibril formation by α-crystallin occurs
within the eye lens. Nevertheless, intuitively the lens environment may be favourable to amyloid fibril
assembly. For instance, the concentration of α-crystallin is high (approximately 150 mg/ml) and there
is very little protein turnover within the avascular lens and it contains proteins as old as the individual
[2]. With time, there is a mounting strain of longevity exerted on the crystallins as they degrade and
undergo an increasing level of post-transitional modifications in old age (e.g. truncation,
phosphorylation, glycation, deamidation) that could lead to destabilization of their native state [61].
Furthermore, crystallin protein aggregation occurs slowly. As a result of these factors, an opportunity
may arise for the crystallins to rearrange and self-assemble into amyloid fibrils. Furthermore,
Frederikse reported that healthy mammalian eye lenses stain positively with the amyloidophilic dyes
Congo red and Thioflavin [62], implying that crystallins in the lens reside in a ‘amyloid-like’ β-sheet
supramolecular structure [62], and thus it is conceivable that the conformational change required to
form amyloid fibrils could be relatively minor. Additionally, as summarized above, the sHsp αcrystallin readily forms amyloid fibrils in vitro when subjected to partially destabilizing conditions
[38].

Further work is required, however, to determine whether many forms of cataract can be attributed to
amyloid fibril aggregation, and additionally the role α-crystallin may play in this process, i.e. whether
it suppresses amyloid assembly by the other lens crystallins (i.e. β- and γ-crystallin), and/or whether it
forms amyloid fibrils itself in the eye lens.

4.2 Amyloid fibril formation by R120G αB-crystallin leads to desmin-related cardiomyopathy
(DRM).
The naturally occurring missense mutant R120G αB-crystallin causes desmin-related cardiomyopathy
(DRM), an autosomal dominant disorder presenting in late adulthood with symptoms of
cardiomyopathy, cataract, and desmin aggregation in muscles [63, 64]. The exact nature and causes of
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the pathogenicity involved in R120G αB-crystallin-induced cardiomyopathy remain to be fully
understood, although reductive stress is likely to play an important role [65]. Parallels have been
drawn, however, between DRM and neurodegenerative diseases such as AD [66], and the pathogenic
processes associated with DRM may additionally involve the formation of toxic amyloid oligomers by
R120G αB-crystallin [67]. Electron dense deposits have been identified containing R120G αBcrystallin which stain positively with the dye Congo red and are also immunoreactive with
conformationally dependent epitope antibodies that recognize amyloid oligomers [67]. In a cardiacspecific transgenic mouse model of this disease, R120G αB-crystallin amyloid oligomer formation
produced mitochondrial dysfunction and apoptosis [68]. Terminating R120G αB-crystallin expression
resulted in a decrease in amyloid oligomer formation and rescued the transgenic animals from
premature death [69]. Prolonged voluntary exercise of the mice was also shown to reduce amyloid
oligomer levels and slow the progression to heart failure [66].
In comparison to the wild-type protein, R120G αB-crystallin has a significantly destabilized structure
that has the tendency to aggregate [70]. It readily forms amyloid fibrils in vitro, and possesses
structural properties akin to fibrils formed from the wild-type protein, including an apparently
identical morphology (as visualized by TEM) and a similar cross-β X-ray fibre diffraction pattern [39].
Amyloid formation by R120G αB-crystallin occurs with a slower growth rate than the wild-type
protein in vitro. Given early amyloid oligomers are toxic to cells [20], the ability of R120G αBcrystallin to persist in this form was suggested to be consistent with its potentially pathogenic role in
vivo [39].
Sanbe et al. [71] showed that recombinant R120G αB-crystallin forms toxic amyloid oligomers in
vitro, approximately 240-480 kDa in mass. The addition of other sHsps, Hsp22 and Hsp25, blocked
oligomer formation by R120G αB-crystallin and recovered cell viability in a cardiomyocyte-based
based study, whereas wild-type αB-crystallin enhanced cell toxicity, suggesting that the mutant and
wild-type αB-crystallin co-aggregate as toxic oligomers [71]. Thus, one therapeutic approach in the
treatment of DRM may involve elevating cellular levels of Hsp22 and Hsp25.
5. sHsps are associated with amyloid plaques and deposits in protein conformational diseases.
Apart from their ability to form amyloid fibrils when placed under destabilising conditions (see
above), there is a growing body of evidence to show that the chaperone activity of sHsps prevents
other proteins from forming amyloid fibrils and that sHsps are intimately associated with protein
conformational diseases [37]. For example, sHsps have been found within amyloid fibril deposits and
plaques [72-76] and the expression of some sHsps is dramatically up-regulated in response to
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pathological conditions associated with fibril formation, e.g. in Dementia with Lewy bodies [75, 77],
Alexander’s disease [78-80], Creutzfeldt–Jakob disease [72], AD [73, 81] and other neurological
conditions [82, 83]. The up-regulation of sHsps expression is presumably a stress response, at the
cellular level, to the aggregating species and is thought to reflect an attempt by the cell to mitigate
fibril formation.

It remains to be established what effect sHsps have on the toxicity associated with fibril formation. In
transgenic Caenorhabditis elegans worms, the expression of human Aβ(1-42) led to the induction of
Hsp16 proteins (which are homologs of αB-crystallin in vertebrates) [84]. Moreover, the Hsp16
proteins co-localized and co-immunoprecipitated with Aβ(1-42) in this model [84] and increasing the
expression of Hsp16 partially suppressed the Aβ-mediated toxicity to these worms [85]. Similarly, the
toxicity associated with ataxin-3 aggregation in a Drosophila model of spinocerebellar ataxia type-3 (a
poly-glutamine mediated protein conformational disease) was reduced when αB-crystallin was overexpressed in this system [86]. Cell-culture models of α-synuclein aggregation have shown that the
mammalian sHsp, Hsp27, inhibits both the aggregation and toxicity associated with this process [77,
87]. It was concluded from both the Aβ and α-synuclein studies that sHsps inhibit fibril formation by
acting early during the aggregation process to prevent the formation of toxic species [85] [77, 87].
This finding is supported by in vitro studies into the ability of sHsps to inhibit amyloid fibril formation
(see below).
A possible mechanism by which sHsps may prevent cytotoxicity associated with fibril formation is
suggested by studies showing that Hsp27 and αB-crystallin increase the resistance of cultured cells
[88-90] and mice [65, 91] to oxidative stress. This may be significant with regard to amyloid fibril
formation since it has been reported that the toxicity of prefibrillar amyloid species is due to the
production of reactive oxygen species by the aggregating fibril-forming protein, which are generated
as a consequence of fibril formation [92]. Therefore, sHsps may protect cells from the cytotoxic
effects of fibril formation both through their ability to inhibit the process directly and to mediate the
redox resistance of cells.
5.1 sHsps inhibit amyloid fibril formation in vitro.
Despite the up-regulation of sHsp expression and their co-localization with amyloid fibril deposits in
various protein conformational diseases, the precise role of sHsps in interacting with the aggregating,
fibril-forming target protein remains to be established [37]. The in vitro inhibition of fibril formation
by sHsps of a variety of target proteins has now been demonstrated. For example, αB-crystallin, the
most studied sHsp in this context, inhibits the fibrillation of α-synuclein [93-95], β2-microglobulin
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[96] (Esposito, Carver, et al., unpublished results), κ-casein [97, 98], insulin [99], the synthetic ccβTrp peptide [97], apolipoprotein C-II [100], and the prion protein (Ecroyd, unpublished results).
Whilst there has been some conjecture over whether sHsps are able to inhibit fibril formation by the
Aβ peptides [96, 101-103], our recent results suggest that αB-crystallin is a potent inhibitor of fibril
formation by Aβ1-40 and Aβ1-42 and, in doing so also prevents the cytotoxicity associated with this
process (Dehle, Ecroyd, Carver, unpublished results). Thus, along with the well established activity of
sHsps to inhibit the disordered (amorphous) forms of protein aggregation, it is evident that sHsps also
have a generic ability to inhibit ordered amyloid fibril protein aggregation. However, the
mechanism(s) by which sHsps inhibit fibril formation appear to vary, not only from the one(s) utilised
to inhibit amorphous aggregation, but also between different fibril-forming target proteins and under
various solution conditions [97].

5.2 Mechanisms by which sHsps inhibit amyloid fibril formation.
αB-Crystallin acts at very low sub-stoichiometric ratios to prevent fibril formation by apolipoprotein
C-II and does so by forming a transient complex with the partially folded form of the protein, which
stabilizes it and enables it to refold back to its native state via the reversible on-folding pathway [100].
In contrast, when αB-crystallin prevents fibril formation by α-synuclein [93, 94] and κ-casein [97], it
does so by forming a stable, soluble chaperone-target protein complex with the target protein (i.e. a
‘reservoir of intermediates’) in a manner presumed to be analogous to the mechanism of chaperone
action used by sHsps against amorphously aggregating proteins [9]. In addition, in the case of αsynuclein, αB-crystallin redirects the protein from the amyloid fibril-forming pathway to the
amorphous aggregation pathway [93], a process that is similar to the mechanism by which the
polyphenol (-)-epigallocatechin-3-gallate (EGCG) inhibits fibril formation [104]. Redirecting the
aggregation of a target protein from an ordered (amyloid fibril) to disordered (amorphous) pathway
would benefit the cell since amorphous aggregates are typically non-toxic and more easily degraded
via the ubiquitin-proteasome system.

There are also mechanistic differences in the manner by which sHsps interact with and inhibit protein
aggregation leading to amyloid fibril formation as compared to amorphous aggregation. This
conclusion is based on studies which have compared the chaperone activity of mutant and/or chimeric
forms of sHsps against amorphous and amyloid fibril-forming target proteins. For example, Raman et
al. (2005) [96], using chimeric α-crystallin proteins, in which the N-terminal domain of αA-crystallin
was fused with the C-terminal domain of αB-crystallin (αANBC) and vice-versa (αBNAC), showed
that whilst αANBC has no ability to prevent the reduction-induced amorphous aggregation of insulin
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B-chain [105], it was as effective as wild-type αA-crystallin in inhibiting amyloid fibril formation by
Aβ(1-40) and β2-microglobulin [96]. Similarly, the chaperone activity of the R120G αB-crystallin
mutant (which, as discussed above, is linked to DRM and early onset cataract [64, 106, 107]) towards
amorphously aggregating target proteins is significantly reduced compared to the wild-type protein
[70, 108], however, its ability to prevent fibril formation by Aβ(1-40) is only slightly reduced [96]. A
double mutant (E164A/E165A αB-crystallin) in the highly flexible and unstructured C-terminal
extension of αB-crystallin [6, 9, 50, 58], had a markedly reduced ability to inhibit the reductioninduced amorphous aggregation of insulin and heat-induced amorphous aggregation of βL-crystallin,
but significantly increased capacity to prevent fibril formation by κ-casein and ccβ-Trp [109].
Together, these results indicate that there are distinct differences in the mechanism by which sHsps
inhibit these two modes of protein aggregation. Interestingly, this raises the possibility that mutant
forms of sHsps may be designed as more effective inhibitors of fibril formation compared to the wildtype protein and therefore may be an avenue for therapeutic potential in the future [109].

Recent work has shown that sHsps interact directly with amyloid fibrils by binding along their length,
inhibiting their further aggregation and ability to ‘seed’ the formation of more fibrils [96, 99]
(unpublished data). αB-Crystallin does not, however, have the ability to disassemble preformed fibrils
[94]. The binding of αB-crystallin to fibrils is intriguing, as such a process may help to explain why
sHsps are associated with amyloid deposits and plaques in protein conformational diseases (see
above). Moreover, our recent results suggest that the interaction of αB-crystallin with preformed
fibrils may result in them tangling and therefore the interaction of Hsps with fibrils may expedite
plaque formation in vivo. Further studies in this exciting new area of sHsp-fibril research will
hopefully shed more light on this interaction and the consequence for plaque progression in diseases
associated with fibril formation.

6. Summary
Overall, a range of studies have demonstrated that the sHsp α-crystallin readily assembles into
amyloid fibrils in vitro when subjected to partially destabilizing conditions. The potential role of
amyloid fibril formation by α-crystallin in the bio-nanomaterial industry, and also in diseases such as
cataract and DRM has been discussed. Whilst amyloid fibril assembly by other sHsps has not been
reported to date, given that the central α-crystallin domain (of approximately 90 amino acids in length)
is conserved between all sHsps and is likely to adopt a β-sandwich structure, these proteins may also
have the potential to form amyloid fibrils. Additionally, there may be a close relationship between
sHsp chaperone action and the propensity to self-aggregate and form fibrils, since both these activities
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are favoured by exposed stretches of hydrophobicity. It is interesting that α-crystallin (along with
other crystallins) adopts an amyloid-like ordered structure within the healthy eye lens. Overall,
therefore, there may be a delicate balance between the structure and chaperone function of the native
α-crystallin oligomer and the formation of amyloid fibrils. With regard to their ability to inhibit
protein aggregation, including amyloid fibril formation, sHsps have significant therapeutic potential
[83, 110, 111]. For example, sHsps could be used directly to suppress protein aggregation whereby
enhancing their expression and/or chaperone ability chemically or by mutagenesis would have
therapeutic application in the treatment of cataract and other protein misfolding diseases.
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10. Figure legends

Figure 1. Amyloid fibrils arise from the association of a partially structured intermediate that deviates
from the protein folding pathway. In this pathway, proteins move from their unfolded to folded/native
states via an intermediate or intermediates. Amorphous aggregates arise from these states via relatively
rapid association that leads to disordered precipitates whereas the formation of fibrils occurs over a
longer timeframe via a nucleation and ordered growth mechanism involving a soluble precursor.

Figure 2. Schematic of sHsp chaperone action with amorphously aggregating proteins [6, 112]. Along
the rapid folding pathway, the intermediately folded states of proteins are transiently present. The offfolding pathway is slow by comparison. As a result, the more disordered intermediate or molten
globule (M.G.) state of the target protein (I2), which is highly dynamic and displays significant
hydrophobicity to solution, is present for a significant period of time and therefore has the propensity
to aggregate along the off-folding pathway via a nucleation-dependent mechanism. sHsps exist as
large, dynamic aggregates which are in constant exchange with dissociated, probably dimeric species.
The dissociated sHsp may be more chaperone-active than the aggregated species, potentially via
exposure of its chaperone binding site region during subunit dissociation. The aggregation of I2 is also
a dynamic process involving equilibria between various aggregated species. The dynamic nature of
both protein species may be the trigger that facilitates sequestration of I2 by the sHsp dimer. In support
of this, sHsps specifically interact with target proteins that are aggregating via a nucleation-dependent
mechanism [113]. Following binding to I2, the complex is incorporated into a high-molecular mass
aggregate. Refolding of I2 to the native state (N) can occur via the action of another chaperone protein,
e.g. Hsp70, which requires the hydrolysis of ATP. The squiggly lines on the surface of the sHsp
oligomer and dimer represent the highly mobile and unstructured region of the C-terminal extensions
[6, 49, 50, 58].

Figure 3. Structural model of an amyloid fibril, formed by the SH3 domain derived from cryo-EM and
X-ray fibre diffraction data (reproduced from [29]). An amyloid fibril is a highly structured
arrangement of the polypeptide chain that is characterised by an array of stacked cross β-sheets (b,d).
The individual β-strands are oriented perpendicular to the long axis of the fibril (b,d) and stack to form
protofilaments (b). The fibril may comprise more than one twisted protofilament, i.e. four in this case
(a,c,d) which helically assemble into the overall fibril structure (a). Fibrils can be very long (hundreds
of nm in length) (c), and may be highly stable and insoluble when sufficiently large (Fig. 1). The
amyloid fibril is proposed to be a generic structure that is accessible to all polypeptide chains
irrespective of their sequence [3].
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Figure 4. A-D, Transmission electron microscopy (TEM) images of amyloid fibrils formed from A,
bovine α-crystallin (purified); B, human recombinant αA-crystallin; C, human recombinant αBcrystallin; and D, human recombinant R120G αB-crystallin. Amyloid fibrils were formed by
dissolving the protein at 1 mg/ml in the presence of 1 M guanidine hydrochloride (GdnHCl) (pH 7.4)
and incubating at 60 °C for 2-24 h.

E-G, Atomic force microscopy (AFM) images of human

recombinant αB-crystallin fibril solutions prepared at pH 7.4 with GdnHCl, then, following a ten-fold
(F), or one 100-fold (G), dilution into a pH 2.0 solution. In A-D, the scale bars represent 200 nm and
in E-G, the scale bars represent 500 nm.
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Table 1. Summary of in vitro studies of amyloid fibril formation by α-crystallins.
sHsps
αT-Crystallin, mixture of αA + αB-crystallin
αT-Crystallin, mixture of αA + αB-crystallin
Wild-type αA-crystallin, 173 aa
αA-Crystallin, range of peptide fragments
Wild-type αB-crystallin, 175 aa
R120G αB-crystallin, 175 aa

Protein Source
Bovine lenses (purified)
Bovine lenses (crude extracts)
Human recombinant
Human recombinant
Human recombinant
Human recombinant

Ref.
[38]
[41]
[39]
[40]
[39]
[39]
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